Menu Search
Equities

Shionogi & Co Ltd

4507:TYO

Shionogi & Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)6,393.00
  • Today's Change90.00 / 1.43%
  • Shares traded739.90k
  • 1 Year change-5.20%
  • Beta0.7666
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 17-Sep-24
Select bar for recommendation details.
Recommendations17-Sep-24
Buy2
Outperform4
Hold6
Sell0
Strong Sell1

Share price forecast in JPY

The 12 analysts offering 12 month price targets for Shionogi & Co Ltd have a median target of 7,100.00, with a high estimate of 8,700.00 and a low estimate of 5,400.00. The median estimate represents a 11.06% increase from the last price of 6,393.00.
High36.1%8,700.00
Med11.1%7,100.00
Low-15.5%5,400.00

Dividends in JPY

In 2024, Shionogi & Co Ltd reported a dividend of 160.00 JPY, which represents a 18.52% increase over last year. The 12 analysts covering the company expect dividends of 169.33 JPY for the upcoming fiscal year, an increase of 5.83%.
Div growth (TTM)18.52%
More ▼

Earnings history & estimates in JPY

On Jul 29, 2024, Shionogi & Co Ltd reported 1st quarter 2025 earnings of 108.07 per share.
The next earnings announcement is expected on Oct 29, 2024.
Average growth rate-6.13%
Shionogi & Co Ltd reported annual 2024 earnings of 558.51 per share on May 13, 2024.
Average growth rate+12.66%
More ▼

Revenue history & estimates in JPY

Shionogi & Co., Ltd. had 1st quarter 2025 revenues of 97.59m. This missed the 99.82m consensus estimate of the 5 analysts following the company. This was 10.73% below the prior year's 1st quarter results.
Average growth rate-2.42%
Shionogi & Co., Ltd. had revenues for the full year 2024 of 435.08m. This was 1.97% above the prior year's results.
Average growth rate+7.69%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.